Leading Edge Acceleration Projects (LEAP) in Health Information Technology (Health IT) Notice of Funding Opportunity (NOFO)

ASTP published a Special Emphasis Notice (SEN) under the Leading Edge Acceleration Projects (LEAP) in Health Information Technology (Health IT) funding opportunity NAP-AX-22-001. In fiscal year 2025, ASTP seeks applications pursuant to the LEAP in Health IT notice of funding opportunity for projects that address one of the following areas of interests:

  • Area 1: Demonstrate readiness of FHIR®-based Subscriptions capability     as a foundational health IT capability for improved interactivity with     third-party applications.
  • Area 2: Identify and test innovative technical approaches that     would inform future changes to the TEFCATM infrastructure     to increase adoption of Individual Access Service (IAS).

For area of interest 1: Demonstrate readiness of HL7® FHIR®-based Subscriptions capability as a foundational health IT capability for improved interactivity with thirdparty applications.

Applicant and their proposed project team should demonstrate familiarity with and understanding of the following:

  • Experience with developing applications using HL7® FHIR® Release
  • 0.1. 2
  • Familiarity with HL7® FHIR® Subscriptions capability.
  • Experience with engaging health IT standards community
  • Experience with developing patient-facing apps using HL7® FHIR®

For area of interest 2: Identify and test innovative technical approaches that would inform future changes to the TEFCA infrastructure to increase adoption of IAS.

Applicant and their proposed project team should demonstrate familiarity with and understanding of the following:

  • TEFCA, including its technical and the policy components.
  • Understanding of IAS in TEFCA.
  • Understanding of health IT networks
  • Developing patient-facing apps using HL7® FHIR®

More here.

Ad



Not Yet a Premium Partner/Sponsor? Learn more about the OS AI Premium Corporate and Individual Plans here. Plans start at $295 annually.

LEAVE A REPLY

Please enter your comment!
Please enter your name here